RARA CRAFT DATABASE for FDA Medical Devices

FDA Device Decisions, April 2026: MRI Software for Parkinsonian Syndromes, Three De Novo Grants and One Original PMA

日本語版

One of FDA's three De Novo grants in April 2026 went to neuropacs (DEN240071), software that analyzes diffusion MRI to help differentiate Parkinson's disease from the parkinsonian variant of multiple system atrophy and from progressive supranuclear palsy. The grant created a new classification, "Parkinsonian syndrome diagnostic aid."

The output is supplemental information for neuroradiologists and neurologists, used with a standard neurological assessment, and the indications say it is to be used only after clinicians have ruled out other causes of parkinsonism.

Counting records held in RA Craft Database (decisions through August 31, 2026, tallied October 6), FDA cleared 314 510(k)s in April 2026, granted 3 De Novo requests and approved 1 original PMA. These counts have not been reconciled with FDA's own figures. The site holds 510(k), De Novo and PMA records from 2015 onward, and counts for past months can change as the data are updated.

Counts by pathway

April 2026 next to the previous month and the same month a year earlier, with records assigned to a month by FDA decision date.

PathwayApril 2026March 2026April 2025
510(k)314299281
De Novo324
PMA (original)143
PMA supplement209170187

Records held in RA Craft Database, decisions through August 31, 2026.

510(k) clearances were 15 more than in March and above April 2025 (281). There was one original PMA.

The busiest product codes

April's 510(k)s spread across 207 product codes. QIH (automated radiological image processing software) led with 10, followed by HGX (pump, breast, powered) with 8, DYB (introducer, catheter) with 7 and HRS (plate, fixation, bone) with 6. DXN (non-invasive blood pressure measurement system), EBF (material, tooth shade, resin), GEI (electrosurgical, cutting & coagulation & accessories), GEX (powered laser surgical instrument) and NKB (thoracolumbosacral pedicle screw system) had 5 each. A single 510(k) can carry more than one product code, so per-code counts can add up to more than the number of submissions. If your code is on the list, enter it in the Product Code field on Search to see the records sorted by decision date.

De Novo: three classifications

April's three De Novo grants, all Class II, with the classification names and regulation numbers from each Classification Order:

  • neuropacs (DEN240071, Automated Imaging Diagnostics, LLC): Parkinsonian syndrome diagnostic aid (21 CFR 882.2000)
  • XplantR Explant Tool (DEN250033, Hjarta Care, LLC): Device for open surgical explant of endovascular prostheses (21 CFR 870.4520)
  • Aurie System (DEN250023, Cathbuddy, Inc.): Reusable intermittent urinary catheter system (21 CFR 876.5120)

"21 CFR" refers to Title 21 of the Code of Federal Regulations, where FDA's regulations are codified.

XplantR helps disengage a stent graft from the aorta during open surgical conversion after endovascular aneurysm repair. Its labeling must identify available resources for user training.

Original PMAs: one approval

  • NEXUS Aortic Arch Stent Graft System (P250033, Endospan, Ltd.): a stent graft system for chronic dissections involving the aortic arch in patients at high risk for open surgical repair (product code SDZ)

April also brought 209 PMA supplements, which cover changes to already approved PMA devices among other things.

Three devices worth a closer read

1. neuropacs (DEN240071, De Novo). For patients aged 40 and older with Parkinson's disease, multiple system atrophy of the parkinsonian type (MSA-P) or progressive supranuclear palsy (PSP). The indications require other causes, such as dementia with Lewy bodies or drug-induced parkinsonism, to be ruled out first, and state that patient management decisions should not rest on the analysis alone. Among its three special controls, the labeling must state that the device is not a stand-alone diagnostic and describe the population used to develop the algorithm.

2. Aurie System (DEN250023, De Novo). A reusable intermittent catheter system for adult men. Before each use, the patient cleans and high-level disinfects the catheter at home in a dedicated washer-disinfector. The nine special controls include reprocessing validation, human factors testing, a use-limitation mechanism and software verification. The device is reprocessed by the patient rather than a hospital, and the classification is written around that fact.

3. NEXUS Aortic Arch Stent Graft System (P250033, PMA). An endovascular option for chronic aortic arch dissection without open surgery. According to the Summary of Safety and Effectiveness Data (SSED) that FDA published with the approval, the single-arm multicenter TRIOMPHE study enrolled 60 patients and met both primary endpoints against their performance goals. The device received Breakthrough Device designation in 2020. Conditions of approval include five-year follow-up of the study cohort and a new post-approval study of at least 135 patients followed to 10 years.

Compare the three devices

Open DEN240071, DEN250023 and P250033, star (☆) each one, tick "Compare" on all three in My Workspace and press "3 selected for comparison". The comparison table puts their Indications for Use side by side. Before relying on any of this, open "FDA Record" and "Summary PDF" on each record and read the source.

Note: months are assigned by FDA decision date, and counts can change as the data are updated each month.

RA Craft Database is an independent service and is not affiliated with or endorsed by the U.S. FDA. Articles are for general information on product development and regulatory research; they are not legal or regulatory advice for a specific device. Official FDA documents remain the authoritative source.

← All articles